If you have been reading about methionine sulfoxide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-18. Numbers and descriptions here follow the published literature rather than marketing material.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
| Property | Value | Notes |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Heptapeptide; ACTH(4-10) analog extended at C-terminus |
| Molecular mass | ~813.9 Da | Free peptide, unmodified |
| Appearance | White to off-white powder | Typical lyophilized solid |
| Solubility | Soluble in water and saline | Also soluble in common aqueous buffers |
| Storage (solid) | -20 °C, desiccated | Protect from moisture and repeated thawing |
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Haycocknema perplexum are parasitic nematodes which reside in tissue under the skin or in blood vessels. The origin of their natural host is unknown. This group comprises 8% of nematode species affecting vertebrates. Clinical symptoms of haycocknema perplexum include eosinophilia and high levels of creatine kinase. While rare, with only thirteen documented cases, all originating in Australia, this parasite can become fatal if left untreated due to muscular dystrophy of the respiratory system. The first case was documented in 1998, and no cases in non-human animals have been reported as of 2022. Only one documented death from complications of infection has been recorded. The current treatment for the parasite is 400 mg of Albendazole. The broad-spectrum anthelmintic drug can treat diseases by impairing the parasite's ability to absorb glucose, resulting in its death.
An alternating copolymer has regular alternating A and B units, and is often described by the formula: -A-B-A-B-A-B-A-B-A-B-, or -(-A-B-)n-. The molar ratio of each monomer in the polymer is normally close to one, which happens when the reactivity ratios r1 and r2 are close to zero, as can be seen from the Mayo–Lewis equation. For example, in the free-radical copolymerization of styrene maleic anhydride copolymer, r1 = 0.097 and r2 = 0.001, so that most chains ending in styrene add a maleic anhydride unit, and almost all chains ending in maleic anhydride add a styrene unit. This leads to a predominantly alternating structure. A step-growth copolymer -(-A-A-B-B-)n- formed by the condensation of two bifunctional monomers A–A and B–B is in principle a perfectly alternating copolymer of these two monomers, but is usually considered as a homopolymer of the dimeric repeat unit A-A-B-B. An example is nylon 66 with repeat unit -OC-( CH2)4-CO-NH-(CH2)6-NH-, formed from a dicarboxylic acid monomer and a diamine monomer.
=== HHV-6 receptor === When an extracellular HHV-6 virion comes across human cells, it encounters the human receptor protein cluster of differentiation 46 (CD46), which plays a role in regulating the complement system. The CD46 protein possesses a single variable region, as a result of alternative splicing. As such, at least fourteen isoforms of CD46 exist, all of which bind HHV-6a. The extracellular region of CD46 contains four short consensus repeats of about 60 amino acids that fold into a compact beta-barrel domain surrounded by flexible loops. As has been demonstrated for CD46 with other ligands, the CD46 protein structure linearizes upon binding HHV-6. While their precise interaction has not yet been determined, the second and third SCR domains have been demonstrated as required for HHV-6 receptor binding and cellular entry.
de novo mutation A spontaneous mutation in the genome of an individual organism that is new to that organism's lineage, having first appeared in a germ cell of one of the organism's parents or in the fertilized egg that develops into the organism; i.e. a mutation that was not present in either parent's genome.
Sources: en.wikipedia.org
The virus has been used for cyber warfare against the national oil companies Saudi Aramco and Qatar's RasGas. Saudi Aramco announced the attack on their Facebook page and went offline again until a company statement was issued on 25 August 2012. The statement falsely reported normal business was resumed on 25 August 2012. However a Middle Eastern journalist leaked photographs taken on 1 September 2012 showing kilometers of petrol trucks unable to be loaded due to backed business systems still inoperable. On 29 August 2012 the same attackers behind Shamoon posted another pastie on PasteBin.com, taunting Saudi Aramco with proof they still retained access to the company network. The post contained the username and password on security and network equipment and the new password for the CEO Khalid Al- Falih The attackers also referenced a portion of the Shamoon malware as further proof in the pastie. According to Kubecka, in order to restore operations. Saudi Aramco used its large private fleet of aircraft and available funds to purchase much of the world's hard drives, driving the price up. New hard drives were required as quickly as possible so oil prices were not affected by speculation. By 1 September 2012 gasoline resources were dwindling for the public of Saudi Arabia 17 days after the 15 August attack. RasGas was also affected by a different variant, crippling them in a similar manner.
== Tissue damage == The tissue damage depends primarily on the absorbed energy and the tissue sensitivity; it is a function of the microwave power density (which depends on the distance from the source and its power output), frequency, absorption rate in the given tissue, and the tissue sensitivity. Tissues with high water (respectively electrolyte) content show higher microwave absorption. The degree of the tissue damage depends on both the achieved temperature and the length of exposure. For short times, higher temperatures can be tolerated. The damage can be spread over a large area, when the source is a relatively distant energy radiator, or a very small (though possibly deep) area, when the body comes to a direct contact with the source (e.g. a wire or a connector pin). The epidermis has high electrical resistance for lower frequencies; at higher frequencies, the energy penetrates through by capacitive coupling. Damage to epidermis has low extent unless the epidermis is very moist. The characteristic depth for lower-frequency microwave injury is about 1 cm. The heating rate of adipose tissue is much lower than that of muscle tissue. Frequencies in millimeter wave range are absorbed in the topmost layer of skin, which is rich in thermal sensors. At lower frequencies, between 1–10 GHz, most of the energy is however absorbed in deeper layers; the threshold for cellular injury there lies at 42 °C while the pain threshold is at 45 °C, so a subjective perception may not be a reliable indicator of a harmful level of exposure at those frequencies.
A measure to determine the CPU speed. It was invented by Linus Torvalds and is nowadays present on every Linux operating system. However, it is not a meaningful measure to assess the actual CPU performance.
== Diagnosis == The diagnosis of MADD needs to be considered in patients who have exercise induced myalgia, cramps and sometimes weakness. A mildly elevated creatine kinase may also occur. Exclusion of other muscular diseases such as McArdle's Disease and carnitine cycle abnormalities should occur. MADD may be identified if there is a lack of ammonia rise after forearm exercise testing. The diagnosis may then be confirmed with genetic testing.
An attempted motorcycle bomb attack on a Police APC was foiled in Lakki Marwat District. On 12 June, an alleged TTP commander was killed in a police operation in Bannu District, two bodies of civilians killed by militants were also recovered and an attempt to destroy a bridge was foiled. Pakistani forces claimed that they had concluded Operation Iron Fist-3, which was carried out from 1-12 June 2026, killing 62 TTP militants including four commanders and capturing eight, destroying 14 militant infrastructure sites, with 48 insurgents being killed in the second phase of operations, according to ISPR. Two civilians were killed and several wounded in a suicide blast near a mosque in Lakki Marwat. On 13 June, a religious scholar was assassinated by TTP and a bridge and a mosque were damaged in an attack by TTP insurgents in Bannu District. CTD captured the brother of an Afghan TTP militant, who himself was allegedly involved in supplying drones, electronic equipment and phones to TTP insurgents. On 14 June, militants attacked a police checkpoint in Kurram District killing a civilian and wounding three police officers, after which militant hideouts were struck by Pakistani artillery fire. 12 insurgents were killed in an infiltration attempt across the border from Afghanistan in Chaman District. Four peace committee members were killed in a TTP attack in Lakki Marwat District and ten suspected insurgents were arrested from Karak District. A TTP drone strike in Kurram District killed four civilians and wounded four more.
Sources: en.wikipedia.org
Seeking to mend ties with the agribusiness sector, the government launched the 2023–2024 Crop Plan, providing R$ 364 billion in rural credit at interest rates below those prevailing in the financial market. This represented a 27% increase in funds compared to the 2022–2023 edition under the previous administration. The "Family Farming Harvest Plan" was also launched, which sought to strengthen family farming by extending rural credit to small and medium landowners, with around R$ 77.7 billion in resources being released for this plan in 2023-2024, a 34% increase in funding compared to the 2022–2023 edition. For the 2024–2025 edition, the government released R$ 400 billion in resources for large landowners, and R$ 85,7 billion for small and medium ones. The 2025–2026 edition released another R$ 516 billion in rural credit for large landowners, and R$ 78,2 billion for family farming. For the 2026–2027 edition, it released R$ 525.1 billion in credit for the agribusiness and another R$ 85 billion for small farms.
Aceclidine is a parasympathomimetic cholinergic drug that functions as a muscarinic acetylcholine receptor agonist. It is used in ophthalmology as a miotic agent to constrict the pupil. Historically used in Europe for the treatment of glaucoma, aceclidine received its first U.S. approval in 2025 under the brand name Vizz as a topical eye drop for the correction of presbyopia. Its mechanism of action produces pupil contraction with a relatively minimal effect on the ciliary muscle, which improves near visual acuity through a "pinhole" depth-of-field effect without inducing significant accommodative spasm.
Alanine (symbol Ala or A), or α-alanine, is an α-amino acid that is used in the biosynthesis of proteins. It contains an amine group and a carboxylic acid group, both attached to the central carbon atom which also carries a methyl group side chain. Consequently it is classified as a non-polar, aliphatic α-amino acid. Under biological conditions, alanine exists in its zwitterionic form with its amine group protonated (as −NH+3) and its carboxyl group deprotonated (as −CO−2). Alanine is encoded by all codons starting with GC (GCU, GCC, GCA, and GCG). The L-isomer of alanine (left-handed) is the one that is incorporated into proteins. L-alanine is second only to L-leucine in rate of occurrence, accounting for 7.8% of the primary structure in a sample of 1,150 proteins. The right-handed form, D-alanine, occurs in peptides in some bacterial cell walls (in peptidoglycan) and in some peptide antibiotics, and occurs in the tissues of many crustaceans and molluscs as an osmolyte. Alanine is not an essential amino acid in humans because it can be synthesized metabolically and does not need to be present in the diet. However hypoalaninemia (alanine deficiency) is possible under certain conditions such as ketotic hypoglycemia.
It can also be used in nuclear synthesis of higher mass elements; oganesson (element 118) was synthesized by bombarding californium-249 atoms with calcium-48 ions. Users of californium must take into account radiological concerns and the element's ability to disrupt the formation of red blood cells by bioaccumulating in skeletal tissue.
Sources: en.wikipedia.org
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.
Its sequence corresponds to the 4-10 region of corticotropin extended by three residues. This fragment lacks the region responsible for adrenal steroid release, so it is explored for neural rather than hormonal effects. The relationship explains the compound's classification among ACTH-derived peptides.
It holds approval in Russia for several neurological indications as a nasal spray or drop formulation. Regulatory agencies in the United States and the European Union have not approved it. Products sold elsewhere are generally labeled for research use only.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.